IRIS
VALENTINI, Gabriele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 24.764
NA - Nord America 10.247
AS - Asia 6.103
SA - Sud America 1.255
Continente sconosciuto - Info sul continente non disponibili 615
AF - Africa 83
OC - Oceania 5
Totale 43.072
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 9.992
RU - Federazione Russa 9.710
IT - Italia 8.622
SG - Singapore 2.338
IE - Irlanda 1.855
CN - Cina 1.266
UA - Ucraina 1.126
BR - Brasile 1.081
HK - Hong Kong 1.047
GB - Regno Unito 867
DE - Germania 635
FR - Francia 587
VN - Vietnam 531
FI - Finlandia 320
NL - Olanda 301
SE - Svezia 253
TR - Turchia 221
GR - Grecia 199
IN - India 167
KR - Corea 165
CA - Canada 150
JP - Giappone 86
BE - Belgio 71
AR - Argentina 59
ES - Italia 54
BD - Bangladesh 49
ID - Indonesia 47
MX - Messico 40
EC - Ecuador 36
CH - Svizzera 34
IQ - Iraq 34
PL - Polonia 31
AT - Austria 26
ZA - Sudafrica 25
CO - Colombia 21
PK - Pakistan 17
UZ - Uzbekistan 17
PY - Paraguay 16
VE - Venezuela 15
CR - Costa Rica 14
RO - Romania 14
TH - Thailandia 14
EG - Egitto 13
EU - Europa 12
MA - Marocco 12
SA - Arabia Saudita 11
AE - Emirati Arabi Uniti 10
CL - Cile 10
JM - Giamaica 10
TW - Taiwan 10
CZ - Repubblica Ceca 9
HR - Croazia 9
HU - Ungheria 9
KZ - Kazakistan 9
UY - Uruguay 9
KE - Kenya 8
TN - Tunisia 8
NI - Nicaragua 7
PE - Perù 7
TT - Trinidad e Tobago 7
AZ - Azerbaigian 6
PH - Filippine 6
BH - Bahrain 5
BY - Bielorussia 5
DZ - Algeria 5
GT - Guatemala 5
HN - Honduras 5
IL - Israele 5
IR - Iran 5
JO - Giordania 5
MY - Malesia 5
NP - Nepal 5
PA - Panama 5
AU - Australia 4
BB - Barbados 4
EE - Estonia 4
KG - Kirghizistan 4
RS - Serbia 4
XK - ???statistics.table.value.countryCode.XK??? 4
DK - Danimarca 3
ET - Etiopia 3
LK - Sri Lanka 3
MK - Macedonia 3
OM - Oman 3
PT - Portogallo 3
SN - Senegal 3
SV - El Salvador 3
AL - Albania 2
AP - ???statistics.table.value.countryCode.AP??? 2
LB - Libano 2
LT - Lituania 2
MN - Mongolia 2
NO - Norvegia 2
QA - Qatar 2
SY - Repubblica araba siriana 2
AO - Angola 1
BG - Bulgaria 1
BN - Brunei Darussalam 1
BO - Bolivia 1
BS - Bahamas 1
Totale 42.459
Salva come PNG Salva come JPEG
Città #
Moscow 3.441
Dublin 1.844
Jacksonville 1.579
Hong Kong 1.039
Santa Clara 882
San Jose 875
Ashburn 845
Singapore 828
Chandler 756
Milan 594
Council Bluffs 579
Rome 560
Princeton 288
Medford 254
Beijing 225
Ho Chi Minh City 203
Naples 190
Ann Arbor 166
Seoul 160
Napoli 156
San Mateo 152
Boardman 148
Roxbury 148
Wilmington 138
Hefei 126
Hanoi 123
Bremen 113
Woodbridge 113
Turin 101
Bengaluru 100
Florence 98
Palermo 93
Dallas 88
Cambridge 83
Bologna 71
São Paulo 70
Bari 68
Catania 67
Des Moines 65
Mountain View 64
Brussels 62
New York 61
Caserta 58
Helsinki 58
The Dalles 55
Ottawa 52
Padova 50
Los Angeles 49
Nanjing 49
Verona 43
Miano 39
Genoa 37
Atlanta 35
Munich 33
Cagliari 31
Da Nang 31
Rio de Janeiro 31
Torino 27
Brasília 26
Pescara 26
Belo Horizonte 25
Toronto 25
Venice 25
Houston 24
Messina 24
Orem 24
Taranto 24
Tokyo 24
Vicenza 24
Mcallen 23
Frankfurt am Main 22
Modena 22
Jinan 21
Nuremberg 21
Redwood City 21
Brescia 20
Guangzhou 20
Livorno 20
Parma 20
Perugia 20
Chicago 19
Haiphong 19
London 19
Montreal 19
Salerno 19
France 18
Genova 18
Baghdad 17
Düsseldorf 17
Kunming 17
Norwalk 17
Trieste 17
Reggio Emilia 16
Changsha 15
Curitiba 15
Gorno 15
Reggio Calabria 15
Shanghai 15
Trento 15
Auburn Hills 14
Totale 19.131
Salva come PNG Salva come JPEG
Nome #
ARTRITE PSORIASICA ED INTERSTIZIOPATIA POLMONARE : DESCRIZIONE DI UN CASO CLINICO. 8.864
Systemic sclerosis associated interstitial lung disease - individualized immunosuppressive therapy and course of lung function: Results of the EUSTAR group 454
ANTI TNF ALFA IN PAZIENTI AFFETTI DA ARTRITE REUMATOIDE E SPONDILOARTRITI HBV CARRIERS OCCULTI:STUDIO RETROSPETTIVO SULLA SICUREZZA 310
Diagnostic issues faced by a rare disease healthcare network during Covid-19 outbreak: data from the Campania Rare Disease Registry 219
A PILOT STUDY ON LOW-DOSE INTRAVENOUS CICLOPHOSPHAMIDE IN SYSTEMIC SCLEROSIS: EFFICACY, SAFETY AND EFFECTS ON CELLULAR ACTIVATION MARKERS 217
Clinical and subclinical atherosclerosis in systemic sclerosis: consequences of previous corticosteroid treatment. 208
Antinuclear antibodies in first-degree relatives of patients with polymyositis-dermatomyositis: analysis of the relationship with HLA haplotypes 196
ANTI-TNFα TREATMENT IS ASSOCIATED WITH INCREASED LIVER STIFFNESS IN HBV OCCULT CARRIER PATIENTS 194
Association between a stromal cell-derived factor 1 (SDF-1/CXCL12) gene polymorphism and microvascular disease in systemic sclerosis 193
Clinical correlates of human leukocyte antigen-G (HLA-G) in systemic sclerosis. 175
[HAQ-DI Italian version in systemic sclerosis]. 172
[Comparison between auranofin and chloroquine in the therapy of rheumatoid arthritis] 172
[T-lymphocyte subpopulations in the conjunctiva of subjects with secondary Sjogren's syndrome] 170
CXCL4 in undifferentiated connective tissue disease at risk for systemic sclerosis (SSc) (previously referred to as very early SSc) 166
Early systemic sclerosis: Analysis of the disease course in patients with marker autoantibody or capillaroscopic positivity or both. 165
Early Systemic Sclerosis: Marker Autoantibody Positive Patients Have A Faster Pace Of The Disease. 161
ACE inhibitors in SSc patients display a risk factor for scleroderma renal crisis-a EUSTAR analysis. 161
Association of a functional polymorphism in the matrix metalloproteinase-12 promoter region with systemic sclerosis in an Italian population 158
Alterazione del riempimento ventricolare sinistro nella sclerosi sistemica (SSc): risultati di uno studio Iongitudinale 158
-238 and +489 TNF-alpha along with TNF-RII gene polymorphisms associate with the diffuse phenotype in patients with Systemic Sclerosis 158
Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis 158
Adult-onset Still's disease: an Italian multicentre retrospective observational study of manifestations and treatments in 245 patients 158
Adult-onset Still's disease: Evaluation of prognostic tools and validation of the systemic score by analysis of 100 cases from three centers 157
Early systemic sclerosis: marker autoantibodies and videocapillaroscopy patterns are each associated with distinct clinical, functional and cellular activation markers. 156
Longterm Hydroxychloroquine Therapy and Low-dose Aspirin May Have an Additive Effectiveness in the Primary Prevention of Cardiovascular Events in Patients with Systemic Lupus Erythematosus 156
ARTHRITIS IS ASSOCIATED WITH PSORIASIS IN PATIENTS WITH INFLAMMATORY BOWEL DISEASES 154
Cardiac involvement in undifferentiated connective tissue disease at risk for systemic sclerosis (otherwise referred to as very early-early systemic sclerosis): a TDI study 153
[Atherosclerosis and rheumatoid arthritis: relationships between intima-media thickness of the common carotid arteries and disease activity and disability]. 151
[Eosinophilic fasciitis. A recently reported oligotopic connective tissue inflammation. A case report] 151
.ANTI-TNF alfa IN PATIENTS WITH EITHER RHEUMATOID ARTHRITIS OR SPONYLOATHRITIS And CONCURRENT C HEPATITIS:A RETROSPECTIVE RECORD REVIEW ON SAFETY 151
Low-dose aspirin as primary prophylaxis for cardiovascular events in systemic lupus erythematosus: A long-term retrospective cohort study 151
[Survival and death causes in 251 systemic sclerosis patients from a single Italian center]. 150
Peripheral blood T lymphocytes from systemic sclerosis patients show both Th1 and Th2 activation 149
"To be or not to be," ten years after: evidence for mixed connective tissue disease as a distinct entity. 149
Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. 149
A genetic variation located in the promoter region of the UPAR (CD87) gene is associated with the vascular complications of systemic sclerosis 148
[A comparison between the Simplified Disease Activity Index (SDAI) and the Disease Activity Score (DAS28) as measure of response to treatment in patients undergoing different therapeutic regimens]. 147
[Italian consensus on the recommendations about the use of methotrexate for the treatment of rheumatic diseases with a focus on rheumatoid arthritis: results from the "3E initiative"]. 146
[Absolute and relative increase in Leu-11b+ cells in patients with systemic scleroderma] 146
[FRI0313] CYCLOPHOSPHAMIDE PULSE THERAPY IN THE TREATMENT OF SYSTEMIC SCLEROSIS-INTERSTITIAL LUNG DISEASE G. Abignano, M. Iudici, A. Petrillo, G. Cuomo, G. Valentini. Rheumatology Unit, Second University of Naples, Napoli, Italy Background: Cyclophosphamide (CYC) is currently used in the treatment of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). A recent meta-analysis1 (Nannini C et al), pooling data from studies based on different entry criteria, questions its usefulness. Objectives: To investigate the effectiveness of low dose pulse CYC (500 mg/dose) in the treatment of recently deteriorating SSc-ILD. Methods: 51 patients with SSc-ILD, all of them satisfying ACR criteria for the classification of the disease and presenting with a recent (<6 months) decrease (≥10% of the predictive value) of either Forced Vital Capacity (FVC) or Diffusing Lung Capacity for CO (DLCO), were enrolled in the study. All of them underwent a concurrent prednisone therapy (10 mg/daily). CYC was administered i.v. at a dose of 500 mg weekly. Total CYC dose ranged from 4.5 to 11.5 g (median 7.5). An increase of 10% in either FVC or DLCO was considered indicative of improvement; a change between <10% and >10% of stable disease; a decrease ≥10% of worsening. Results: 22 out of the 51 SSc patients (43.14%) resulted to improve at the end of the CYC course; 17 (33.33%) remained stable; 12 (23.53%) worsened. No patients withdrew CYC treatment because of side effects. Conclusion: Our study suggests that the effectiveness of CYC in SSc-ILD may depend on entry criteria. Actually about 76% of patients who had experienced a recent deterioration of lung function, suggesting active alveolitis, underwent improvement or stabilization of their disease in our study. References:[ol][li]Nannini C, West CP, Erwin PJ, Matteson EL. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies. Arthritis Res Ther 2008, 10:R124.[/li][/ol]Disclosure of Interest: None declared Ann Rheum Dis 2009;68(Suppl3):460 Session: Scleroderma, myositis and related syndromes 146
Polymorphism of immunoglobulin enhancer element HS1,2A: allele *2 associates with systemic sclerosis. Comparison with HLA-DR and DQ allele frequency 145
A SCLERODERMA PATIENT WITH SWOLLEN AND TENDER JOINTS OF BOTH HANDS 144
PREVALENCE OF ANTIBODIES RECOGNAIZING CYCLIC CITRULLINATED PEPTIDE(anti CCP) IN PATIENTS WITH ULCERATIVE COLITIS 143
[Hypocomplementemia in systemic sclerosis]. 143
Osteopenia in systemic sclerosis. Evidence of a participating role of earlier menopause 142
Early systemic sclerosis: assessment of clinical and pre-clinical organ involvement in patients with different disease features 142
Low-dose intravenous cyclophosphamide in systemic sclerosis: an open prospective efficacy study in patients with early diffuse disease 140
Evaluation of cardiac structures and function in systemic sclerosis by Doppler echocardiography 139
[Epidemiology and risk factors in osteoarthritis: literature review data from "OASIS" study]. 138
Cardiac involvement in rheumatoid arthritis: an echocardiographic study 138
Systemic sclerosis could mask the presentation of psoriasis in a patient with symptomatic and bilateral sacroiliitis 138
Anti-carbamylated protein antibodies and skin involvement in patients with systemic sclerosis: An intriguing association 137
RELAPSING POLYCHONDRITIS. AN HYSTOCHEMICAL STUDY BY LECTIN. 136
Systemic sclerosis: demographic, clinical, and serologic features and survival in 1,012 Italian patients 136
2013 classification criteria for systemic sclerosis: An american college of rheumatology/European league against rheumatism collaborative initiative 136
Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database 135
ANTI-TOPOISOMERASE I (ANTI-SCL-70) AND CANCER IN SYSTEMIC SCLEROSIS. ARE THEY RELATED? 135
The European Scleroderma Trials and Research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: Derivation and validation of a preliminarily revised EUSTAR activity index 135
Low-dose aspirin as primary prophylaxis for cardiovascular events in rheumatoid arthritis: an Italian multicentre retrospective study 135
A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: a EUSTAR prospective study 134
Evidence for peripheral impaired glucose handling in patients with connective tissue diseases 134
ELF Score: A Validated Serum Test Strongly Predictive of Fibrosis in Systemic Sclerosis. 134
Glucocorticoids in systemic sclerosis: patients' beliefs and treatment adherence. 133
[Copernican revolution in the therapy of rheumatoid arthritis: the contribution of anti-TNFalpha drugs]. 132
New strategies to address the pharmacodynamics and pharmacokinetics of tumor necrosis factor (TNF) inhibitors: A systematic analysis. 131
[Rarity of sclerodermic renal crisis in the Italian population and the uncommon nature of the Vogt-Koyanagi-Harada syndrome in systemic sclerosis] 131
EUSTAR biobanking: recommendations for the collection, storage and distribution of biospecimens in scleroderma research 130
Low-dose pulse cyclophosphamide in interstitial lung disease associated with systemic sclerosis (SSc-ILD): Efficacy of maintenance immunosuppression in responders and non-responders. 130
.Spectrum of cardiac involvement in systemic lupus erythematosus: echocardiographic, echo-Doppler observations and immunological investigation. 130
Prevalence of anti-toxoplasma antibodies in patients with autoimmune diseases. 129
Tissue Doppler imaging in systemic sclerosis: A 3-year longitudinal study. 129
[Metabolic syndrome in inflammatory rheumatic diseases]. 129
Non-Hodgkin's lymphoma in systemic sclerosis: case and literature review 129
Brief report: Successful pregnancies but a higher risk of preterm births in systemic sclerosis: An Italian multicentric study. 129
RELATIONSHIP OF THE 6-MIN WALKING TEST AND QUALITY OF LIFE 129
Alterazioni del sistema nervoso autonomo nella Sclerosi Sistemica (SSc). Risultati preliminari di uno studio sul rapporto con la severita della malattia 128
Effects and safety of rituximab in systemic sclerosis: An analysis from the European Scleroderma Trial and Research (EUSTAR) group 127
Impaired exercise performance in systemic sclerosis and its clinical correlations 127
Thrombocytosis in progressive generalized sclerosis (scleroderma) and in other rheumatic diseases 127
Systemic sclerosis 127
European Scleroderma Study Group (ESCSG) Activity Index is correlated to quality of life measures both at admission and overtime 127
Cell-free DNA in the plasma of patients with systemic sclerosis 126
High IL-17E and Low IL-17C Dermal Expression Identifies a Fibrosis-Specific Motif Common to Morphea and Systemic Sclerosis. 126
Quality of life as measured by the short-form 36 (SF-36) questionnaire in patients with early systemic sclerosis and undifferentiated connective tissue disease. 126
ATHEROSCLEROSIS AND RHEUMATOID ARTHRITIS: EVALUATION OF INTIMA-MEDIA THICKNESS AND CORRELATION WITH INFLAMMATORY AND ATHEROGENIC MARKERS 126
Sub-Analysis of ELF Score Biomarkers Components Indicates a Specific Correlation with Different Organ Involvement in Systemic Sclerosis. 126
Low mortality rate in Italian rheumatoid arthritis patients from a tertiary center: Putative implication of a low anti-carbamylated protein antibodies prevalence 126
Twelve-month azathioprine as maintenance therapy in early diffuse systemic sclerosis patients treated for 1-year with low dose cyclophosphamide pulse therapy 125
Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group 124
Diastolic abnormalities in systemic sclerosis: evidence for associated defective cardiac functional reserve 123
Early Systemic Sclerosis: Serum Profiling of Factors Involved in Endothelial, T-cell, and Fibroblast Interplay is Marked by Elevated Interleukin-33 Levels. 123
Severe polymyositis due to Toxoplasma gondii in an adult immunocompetent patient: a case report and review of the literature. 123
VALIDATION OF THE SIMPLIFIED DISEASE ACTIVITY INDEX (SDAI) AND DAS28 AS MEASURE OF RESPONSE TO TREATMENT IN PATIENTS UNDERGOING DIFFERENT THERAPEUTIC REGIMENS 123
Tocilizumab in the treatment of patients with rheumatoid arthritis in real clinical practice: Results of an Italian observational study 123
Peripheral T lymphocytes from patients with early systemic sclerosis co-cultured with autologous fibroblasts undergo an oligoclonal expansion similar to that occurring in the skin 122
Correlations of Y chromosome microchimerism with disease activity in patients with SLE: analysis of preliminary data 122
[The arthropathy of systemic sclerosis]. 122
The incidence of cardiovascular events in Italian patients with systemic lupus erythematosus is lower than in North European and American cohorts: Implication of disease-associated and traditional risk factors as emerged by a 16-year retrospective GIRRCS study 122
Crioglobulinemia mista essenziale: prevalenza e caratteri della neuropatia periferica 121
The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy 120
Totale 23.539
Salva come PNG Salva come JPEG
Categoria #
all - tutte 133.471
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 133.471
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20222.219 0 0 0 103 738 103 106 162 134 120 201 552
2022/20234.527 430 195 113 303 394 316 112 297 1.767 184 204 212
2023/20242.785 195 131 182 285 626 109 189 230 130 161 228 319
2024/20255.492 125 162 120 195 715 859 820 459 612 803 381 241
2025/202616.130 526 591 852 893 1.372 9.137 815 518 686 342 234 164
2026/20273.059 274 407 1.302 1.076 0 0 0 0 0 0 0 0
Totale 43.072